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Abstract
Background:  Neuronal ceroid lipofuscinoses (NCLs) comprise at least eight genetically
characterized neurodegenerative disorders of childhood. Despite of genetic heterogeneity, the
high similarity of clinical symptoms and pathology of different NCL disorders suggest cooperation
between different NCL proteins and common mechanisms of pathogenesis. Here, we have studied
molecular interactions between NCL proteins, concentrating specifically on the interactions of
CLN5, the protein underlying the Finnish variant late infantile form of NCL (vLINCLFin).
Results: We found that CLN5 interacts with several other NCL proteins namely, CLN1/PPT1,
CLN2/TPP1, CLN3, CLN6 and CLN8. Furthermore, analysis of the intracellular targeting of CLN5
together with the interacting NCL proteins revealed that over-expression of PPT1 can facilitate the
lysosomal transport of mutated CLN5FinMajor, normally residing in the ER and in the Golgi complex.
The significance of the novel interaction between CLN5 and PPT1 was further supported by the
finding that CLN5 was also able to bind the F1-ATPase, earlier shown to interact with PPT1.
Conclusion: We have described novel interactions between CLN5 and several NCL proteins,
suggesting a modifying role for these proteins in the pathogenesis of individual NCL disorders.
Among these novel interactions, binding of CLN5 to CLN1/PPT1 is suggested to be the most
significant one, since over-expression of PPT1 was shown to influence on the intracellular
trafficking of mutated CLN5, and they were shown to share a binding partner outside the NCL
protein spectrum.
Background
Neuronal ceroid lipofuscinoses (NCLs) are the most com-
mon group of children's progressive neurodegenerative
disorders with an estimated incidence of 1:12500 in the
USA and Nordic countries and approximately 1:100 000
worldwide [reviewed in [1,2]]. NCL disorders are mostly
recessively inherited, and to date, eight different genes
have been characterized to underlie these diseases [3-5].
Despite having genetic heterogeneity, NCL diseases
resemble each other both clinically and neuropathologi-
cally. The clinical course varies from severe congenital dis-
ease to milder adult-onset forms. NCLs are phenotypically
Published: 26 November 2009
BMC Cell Biology 2009, 10:83 doi:10.1186/1471-2121-10-83
Received: 11 June 2009
Accepted: 26 November 2009
This article is available from: http://www.biomedcentral.com/1471-2121/10/83
© 2009 Lyly et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
Page 2 of 11
(page number not for citation purposes)
expressed by progressive mental deterioration, blindness,
epileptic seizures and premature death. The pathological
findings of these lysosomal storage disorders include
intracellular accumulation of autofluorescent lipopig-
ment with variable ultrastructural appearance as well as
progressive loss of neocortical neurons. The major com-
ponent of the intracellular storage material is either the
subunit c of the mitochondrial ATP synthase [6] or sphin-
golipid activator proteins A and D [5,7]. More recent anal-
yses of different mouse models of NCL have exposed
additional common features in the brain pathology
[reviewed in [8]].
The proteins encoded by NCL genes are localized in differ-
ent compartments of the secretory pathway. Palmitoyl
protein thioesterase 1 (PPT1; CLN1), tripeptidyl-pepti-
dase 1 (TPP1; CLN2) and cathepsin D (CLN10) are solu-
ble lysosomal enzymes [9-11]. CLN3 and the recently
identified MFSD8 (CLN7) are transmembrane proteins
localizing mainly to the late endosomal/lysosomal com-
partments [4,12]. Two of the NCL proteins, CLN6 and
CLN8, reside mainly in the ER [13,14]. Despite the fact
that many NCL proteins were characterized already a dec-
ade ago, the physiological functions of most NCL proteins
are still not known and neither are the molecular connec-
tions between them understood [15]. CLN5 is a glycopro-
tein disrupted in the Finnish variant late infantile form of
NCL (vLINCLFin) [16,17]. The subcellular localization of
overexpressed CLN5 has been studied in BHK-21, HeLa
and COS-1 and cells, where it was found to be lysosomal
[16,18]. In neuronal cells, CLN5 is also present in the cel-
lular extensions, but the specific organelle localization in
neurons is still unidentified [16]. PPT1/CLN1 and CLN3
are also found in neuronal axons, where CLN1 has been
localized to synaptic vesicles and CLN3 to synaptosomes
[19-21]. Controversial data has been reported about the
solubility of the CLN5 protein [16,18,22,23], but both
human and mouse CLN5 have been found in the man-
nose 6-phosphoproteome, supporting the presence of sol-
uble CLN5 variants [24,25]. Overall, the CLN5 protein is
not well conserved, lacks protein homologues and is cur-
rently poorly characterized. Very little is also known about
the interactions between different NCL proteins. Vesa and
co-workers have shown by co-immunoprecipitation and
in vitro binding assays that CLN5 interacts with both
CLN2 and CLN3 [23], but the result has not been verified.
To obtain more knowledge of common pathways in
NCLs, we examined the interactions of CLN5 with other
NCL proteins utilizing pull-down and co-immunoprecip-
itation analyses. We report four novel interactions for
CLN5 and show that PPT1/CLN1 and CLN5 are con-
nected at the level of intracellular trafficking.
Methods
Recombinant CLN5-cDNA constructs
Mouse Cln5-cDNA lacking the suggested signal sequence
(aa 26-341) was cloned in frame with an N-terminal GST-
tag in a pGEX2T vector (Amersham Biosciences). For the
co-immunoprecipitation assay, the full-length mCln5-
cDNA (aa 1-341) was cloned into the pcDNA3.1A/Myc-
His expression vector (Invitrogen) to produce a CLN5
protein with a C-terminal tag. The trafficking-deficient
human CLN5-TD (CLN5 flag330) protein was obtained
by inserting an intramolecular flag sequence after amino
acid 330 into the full-length CLN5 (aa 1-407) pCMV5
construct, using the QuickChange Site-Directed mutagen-
esis kit. All constructs were verified by sequencing.
Cell culture, transfection and immunofluorescence 
analyses
HeLa and COS-1 cells were cultured in Dulbecco's modi-
fied Eagle's medium (DMEM), supplemented with 10%
fetal calf serum (FCS) and 1% antibiotics (penicillin/
streptomycin). For transient transfections, cells were
plated on 6-well plates and the transfection was per-
formed with Lipofectamine™ 2000 (Gibco Life Technolo-
gies) or Fugene HD (Roche Diagnostics) transfection
reagents according to manufacturers' instructions. For
immunofluorescence analysis, transiently transfected cells
were grown on coverslips, fixed with ice-cold methanol 48
h after transfection and stained with the specific antibod-
ies described below. The labeled coverslips were mounted
using GelMount (Biomeda Corp., Foster City, CA) and
visualized using Leica DMR confocal microscope with
TCS NT software (Leica Microscope and Scientific Instru-
ments Group). Adobe Photoshop and Adobe Illustrator
softwares were used for image processing. All transfection
and immunofluorescence experiments were repeated at
least three times.
Antibodies
The human CLN5 protein was detected either with a pol-
yclonal rabbit antibody (1RmI-4) raised against GST-
mCLN5 (aa 40-284) or with a guinea pig antibody
(1GmII-3) raised against GST-mCLN5 (aa 40-341) [16].
PPT1 and CLN2 were detected with anti-PPT1 antibodies
(WB: rabbit polyclonal antibody 8414, 1:500 [19]; IF: rab-
bit polyclonal antibody AA-PPT1, 1:200 [26] and mouse
anti-CLN2 antibody 8C4, 1:20 [27] kindly provided by
Drs. Kida and Golabek (New York, USA). CLN3 was
detected with the peptide antibody 385 [21]. CLN8 was
detected with a rabbit peptide antibody 391 (1:200) [13]
and mouse monoclonal anti-HA antibody (Boehringer
Mannheim). The mouse monoclonal anti-LAMP-1 anti-
body H4A3 (WB, IF 1:200) was obtained from the Devel-
opmental Studies Hybridoma Bank (University of Iowa,
Iowa City). The mouse monoclonal anti-FLAG antibody
was from Sigma and the mouse anti c-myc antibodyBMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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(9E10) and the anti-his antibody from Santa Cruz Bio-
technology. The mouse monoclonal PDI (Protein
Disulfide Isomerase) antibody was obtained from Stress-
gen. The α- and β-subunits of the mitochondrial ATP syn-
thase were detected with monoclonal antibodies from
Molecular Probes. The secondary antibodies used for the
immunofluorescence analyses were from Jackson Immu-
noResearch and HRP-conjugated antibodies used for
Western blot detection were from DAKO.
Mice
Cln1-/- (Ppt1Δex4) mice [28] and Cln5-/- mice [29] used in
this study were maintained on a congenic C57/BL6J strain
background. The study has been carried out following
good practice in laboratory animal handling and the reg-
ulations for handling genetically modified organisms,
and it was approved by the Laboratory Animal Care and
Use Committee of the National Public Health Institute,
Helsinki. Tissues for liver extraction were from adult mice.
Quantitative Real-time PCR
Real-time PCR was performed as described in [29]. In
short, Cln5-/-, Cln1-/- and wild-type cortices were prepared
and total RNA was extracted using RNeasy Mini kit (Qia-
gen) according to the manufacturer's instructions, fol-
lowed by quantification by spectrophotometry. To
average out the inter-individual variability, RNA was
extracted from the whole cortical area of four Cln5-/- mice,
four Cln1-/- mice and four of their respective wt littermates
and pooled together into two wild-type and two knock-
out samples. To eliminate genomic DNA, RNA was treated
with DNAse I (Roche, Mannheim, Germany). The RT reac-
tions were carried out on 300 ng of RNA using TaqMan
Reverse transcription kit with Random hexamer primers
(Applied Biosystems, Foster City, CA) as recommended by
the manufacturer. TaqMan Gene Expression Assays of
selected genes were purchased from Applied Bio systems
(CLN5 Mm00515002_m1, PPT1 Mm00727515_s1). The
mRNA expression levels of these genes and a standard
house-keeping gene, mouse TATA-box binding protein
(Tbp, Mm 00446973_m1), were quantified using real-
time PCR analysis (TaqMan chemistry) on an ABI prism
7700 sequence detection system (PE Applied Bioscience,
Warrington, UK). The PCR reactions (25 μl) were carried
out in triplicate with TaqMan Universal Master Mix
according to the manufacturer's instructions using the fol-
lowing parameters: 50°C for 2 min, 95°C for 10 min, 50
cycles of 95°C for 15 sec, 60°C for 60 min. Relative levels
of the selected genes were calculated using the ΔΔCT
method [30] as described previously [29]. The absolute
change in expression level is given by 2-ΔΔCT. For illustra-
tive purposes, the value for the wt gene expression was set
to 1 and CLN5 as well as PPT1 expression values are
shown relative to that.
GST pull-down assays
The GST-mCLN5 fusion construct was expressed in E. coli
and purified by binding to the glutathione-Sepharose 4B
beads (Amersham Biosciences) for 2 h at 4°C. For the
search of NCL binding partners, cytosolic extracts of COS-
1 cells were prepared by lysing the cells in lysis buffer (25
mM HEPES pH 7.4, 150 mM NaCl, 1 mM EDTA, 0.5% Tri-
ton X-100, 0.5 mM MgCl2 and protease inhibitors) and
removing the cell debris by centrifugation. GST vector
control and GST-mCLN5 fusion protein were incubated
with 4 ml of COS lysates (~2 mg/ml) overnight at 4°C.
The beads were washed five times with lysis buffer and the
samples were separated by SDS-PAGE under reducing
conditions, immunoblotted and probed for different NCL
proteins.
The α- and β-subunits of the mitochondrial ATP synthase
were pulled down with GST-mCLN5 and GST-hPPT128-306
[31] from the enriched lysosomal/mitochondrial fraction
originating from the mouse liver. Briefly, mouse liver of
wt, Cln5-/- or Cln1-/- mouse was homogenized (1 g of liver
in 5 ml of HB) in HB buffer (320 mM saccharose, 4 mM
HEPES pH 7.4, 1 mM MgCl2, 0.5 mM CaCl2 + protease
inhibitors) and centrifuged at 3500 rpm for 10 min at
4°C. The post-nuclear supernatant was transferred to
clean tubes and centrifuged again at 14 000 rpm for 15
min at 4°C. The pellet was then dissolved with 1.5 ml of
EB buffer (100 mM NaCl, 50 mM HEPES pH 7.4, 5 mM
MgCl2, 0.5% Triton X-100 + protease inhibitors). The GST
pull-downs were done by incubating 1 ml (2.5 mg/ml) of
enriched liver lysosomal/mitochondrial fractions with
different GST fusion proteins (GST, GST-mCLN5, GST-
hPPT1) over night at 4°C. The beads were then carefully
washed with the EB buffer. Samples were separated by
SDS-PAGE, immunoblotted and probed for α- and β-sub-
units. All pull-down experiments were repeated at least
twice.
Co-immunoprecipitation assay
PPT1/CLN1 was transiently expressed together with
mCLN5-myc/his or with an OPR1L-his [32] control pro-
tein in COS-1 cells. The cells were lysed into an immuno-
precipitation buffer (IP buffer: 10 mM Hepes pH 7.4, 150
mM NaCl, 0.5 mM MgCl2, 10% glycerol, 0.5% Triton X-
100, + protein inhibitor cocktail) and the cell debris was
removed by centrifugation. Immunoprecipitation was
done by adding a his-specific antibody (1 μg/ml) and
incubating the samples on ice for three hours. Immuno-
complexes were then captured by incubation with Protein
A/G Plus agarose beads (Santa Cruz) over night at 4°C.
Agarose beads were then gently centrifuged (3000 rpm for
30 sec.) and washed three times with the IP-buffer. Sam-
ples were separated by SDS-PAGE, immunoblotted and
probed for PPT1/CLN1.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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Results
Interactions of CLN5 with other NCL proteins
The possible interactions of CLN5 with other NCL pro-
teins were investigated with GST pull-down experiments.
A GST-CLN5 fusion protein expressing the mouse CLN5
lacking the signal sequence (GST-mCLN5aa26-341) was
used to pull down endogenous NCL proteins from both
mouse brain extract and HeLa cell lysates (Additional file
1). To avoid the possible false negative binding results due
to low endogenous levels of most NCL proteins, the pull-
downs were also prepared from lysates of COS-1 cells
transiently transfected with different NCL proteins (Fig.
1). The bound proteins were identified by Western blot
analyses. Vesa and co-workers have previously shown by
co-immunoprecipitation and in vitro-binding assays that
CLN5 interacts with CLN2 and CLN3 [23]. In our pull-
down experiments, we could also capture CLN2 and
CLN3 with GST-mCLN5 (Fig. 1), which was considered to
serve as a positive control for our further pull-down anal-
yses. The CLN2 antibody recognized both the 68 kDa pre-
cursor and the mature, lysosomal 48 kDa form of CLN2
[33] in the cell lysate, but only the mature form showed
prominent binding with GST-mCLN5. This suggests that
the interaction between CLN5 and CLN2 most likely
occurs in the late endocytic compartments. Three novel
interactions between NCL proteins were additionally dis-
covered, as PPT1/CLN1, CLN6 and CLN8 were also
shown to bind to GST-mCLN5 (Fig. 1). All proteins except
CLN8 could also be pulled down endogenously from
brain and HeLa cell lysates (Additional file 1). The specif-
icity of the pull-down experiments was tested by using
LAMP-1, a lysosomal membrane protein, as a control. It
showed no binding to GST-mCLN5 (Fig. 1). After LAMP-
1 detection, the membrane was reprobed with anti-CLN2
antibody as a positive control for the pull-down experi-
ment (data not shown). Altogether, the GST-mCLN5
interactions found here cover both soluble and trans-
membrane NCL proteins residing both in the ER and the
lysosomes, thus suggesting that CLN5 has the capacity to
bind different NCL proteins at different cellular localiza-
tions. This observation indicates that CLN5 may play a
role as a factor that connects different NCL proteins.
Analyses of intracellular trafficking of CLN5 together with 
the interacting proteins
To dissect the role of CLN5 interactions with other NCL
proteins in vivo, we first compared the localization of the
newly characterized interaction partners in wild type and
Cln5-/- mouse fibroblasts [29]. Fibroblasts were transiently
transfected with constructs producing different NCL pro-
teins (CLN1, 3, 6 and 8, whereas CLN2 could be detected
endogenously) and fluorescently labeled with antibodies
against the NCL proteins as well as specific organelle
markers. However, no differences in the localization of
any of the interacting NCL proteins could be detected
between the wild type and Cln5-/- cells (data not shown).
We also studied the possible effects of simultaneous over-
expression of wild type hCLN5 and the interaction part-
ners on the protein localization in HeLa cells. Transient
overexpression did not influence the localization of
CLN1, CLN2, CLN6 or CLN8 (data not shown). The
hydrophobic CLN3 was found in lysosomes, but was
often detected also in the ER together with CLN5, most
probably reflecting a folding defect in a situation in which
two proteins are overexpressed (data not shown). This
could reflect an overloading of the ER protein folding
machinery.
To assess whether severe defects in the transport of CLN5
could affect the localization of any of the interacting pro-
teins, co-expressions were performed using a trafficking-
deficient hCLN5 polypeptide (CLN5-TD), representing a
protein restricted to the ER. The intramolecular insertion
of a flag-tag (CLN5-flag330) restrained the CLN5-TD
polypeptide into the ER in HeLa cells (Fig. 2A-C). Interest-
ingly, when the wild type PPT1/CLN1 was co-expressed
with this ER-resident construct, it was also retained in the
ER (Fig. 2D-F). To control the specificity of the observed
restriction on PPT1 transport by CLN5, PPT1/CLN1 was
also overexpressed together with trafficking-deficient
CLN3-flag434 (data not shown) and ER-resident CLN6
(Fig. 2G-I). Neither of these proteins affected the lyso-
somal trafficking of PPT1/CLN1. The transport of CLN3
from the ER was also delayed when it was co-expressed
Interactions of CLN5 with other NCL proteins Figure 1
Interactions of CLN5 with other NCL proteins. The 
mouse Cln5-cDNA (coding for aa 26-341) was expressed as 
GST fusion protein and used to pull down NCL proteins 
from COS-1 cell lysates. PPT1, CLN3, CLN6-c-myc and 
CLN8-HA were transiently overexpressed in COS-1 cells 
and pulled down with GST-mCLN5 and GST vector control. 
CLN2 and LAMP-1 proteins were endogenous. The bound 
proteins were immunoblotted and detected with specific 
antibodies listed in Methods section.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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with the ER-resident CLN5-TD; CLN3 was detected in the
lysosomes, but was additionally seen in the ER (Fig. 2J-L).
However, the effect was milder compared to that seen
with PPT1/CLN1 and therefore was thought to result from
problems in protein folding in the ER. Trafficking of the
endogenous CLN2 was not altered due to overexpression
of CLN5-TD and it was correctly transported to the lyso-
somes (Fig. 3A-C). As assumed, the ER-resident proteins
CLN6 (Fig. 3D-F) and CLN8 (Fig. 3G-I) remained in the
ER and were not detectably influenced by the transport
defect of CLN5-TD.
Overexpression of wild type PPT1/CLN1 rescues the 
lysosomal trafficking of CLN5FinMajor polypeptide
As the most dramatic influence on the localization of the
binding partners of CLN5 was seen for PPT1/CLN1, it was
of interest to study if the expression of CLN5 possessing
the most common vLINCLFin disease-causing mutation
(p. Y392X, CLN5FinMajor) would also influence the traffick-
ing of PPT1/CLN1. The CLN5FinMajor mutation results in a
truncated polypeptide lacking 16 amino acids from the C-
terminus [17] and it has been demonstrated to localize to
the ER and Golgi instead of lysosomes [18]. Importantly,
this mutant protein represents an ER exit-competent
CLN5, in contrast to the CLN5-TD which is a strict ER-res-
ident. We first expressed the wild type PPT1 with wild type
CLN5 in HeLa cells and found that the two proteins com-
pletely co-localized in the lysosomes (Fig. 4A-C). The
mutated CLN5FinMajor polypeptides expressed alone did
Consequences of the ER-resident trafficking deficient CLN5  on the localization of PPT1/CLN1 and CLN3 in HeLa cells Figure 2
Consequences of the ER-resident trafficking deficient 
CLN5 on the localization of PPT1/CLN1 and CLN3 in 
HeLa cells. HeLa cells were transiently transfected with the 
trafficking deficient CLN5 (CLN5-TD) carrying the intramo-
lecular flag-tag after aa 330, alone, or together with wild type 
PPT1 or CLN3. The cells were fixed with methanol 48 h post 
transfection, stained and analyzed by confocal microscopy. 
CLN5-TD co-localized with the ER marker PDI (A-C). 
When transfected together with PPT1, CLN5-TD retained 
the wild type PPT1 also in the ER (D-F), (compare the two 
cells in E positive for PPT1 with and without CLN5-TD), 
whereas overexpression of the ER resident CLN6 did not 
have an influence on PPT1 trafficking (G-I). The CLN5-TD 
partially affected also the lysosomal targeting of the wild type 
CLN3 (J-L). Scale bar 10 μm.
Consequences of the ER-resident trafficking deficient CLN5  on the localization of CLN2, CLN6 and CLN8 in HeLa cells Figure 3
Consequences of the ER-resident trafficking deficient 
CLN5 on the localization of CLN2, CLN6 and CLN8 
in HeLa cells. HeLa cells were transiently transfected alone 
with the trafficking deficient CLN5 (CLN5-TD) carrying the 
intramolecular flag-tag after aa 330 (A-C) or together with 
wild type CLN6 (D-F) or CLN8 (G-I). The cells were fixed 
with methanol 48 h post transfection, stained and analyzed by 
confocal microscopy. The CLN5-TD did not have an effect 
on the lysosomal localization of endogenous CLN2 (A-C) or 
on the overexpressed ER resident NCL proteins CLN6 (D-
F) and CLN8 (G-I). Scale bar 10 μm.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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not show co-localization with the lysosomal marker,
LAMP-1, but were retained in the ER in HeLa cells (Fig.
4D-F). Interestingly, simultaneous overexpression of wild
type PPT1 with CLN5FinMajor resulted in a positive effect on
the trafficking of the mutated CLN5, and both proteins
were found in the lysosomes (Fig. 4G-K and Additional
file 2). To verify the results obtained in HeLa cells, we
repeated the experiments also in human neuroblastoma
cells (SH-SY5Y). Simultaneous overexpression of wild
type PPT1/CLN1 and CLN5FinMajor in SH-SY5Y cells again
resulted in co-localization of the two proteins in LAMP-1
positive late endosomes/lysosomes, whereas the
CLN5FinMajor expressed alone was detected only in the ER
(Additional file 3). Wild type PPT1/CLN1 seemed thus to
have a positive effect on the transport of CLN5FinMajor
when overexpressed in the same cell, being able to facili-
tate the trafficking of the mutated CLN5 from the ER into
the late endosomal compartments.
PPT1/CLN1 mutants retained in the ER do not restrict the 
lysosomal trafficking of CLN5
As PPT1/CLN1 was found to facilitate trafficking of the
mutated CLN5FinMajor, we wanted to study whether it is a
prerequisite for the lysosomal trafficking of CLN5. We
overexpressed PPT1/CLN1 carrying either the most com-
mon INCL disease mutation (PPT1Fin, p. R122W) [34] or
the adult-onset causing mutation (PPT1Adult, p. G108R)
[35] together with the wt CLN5 in HeLa cells. The locali-
zation of the proteins was then studied by confocal micro-
scopy. Both PPT1Fin (Fig. 5A) and PPT1Adult (data not
shown, [26]) localized to the ER, whereas the wt CLN5
was found in the lysosomes (Fig. 5A). The mutated PPT1/
CLN1 proteins were never detected in lysosomes suggest-
ing that CLN5 lacks the positive targeting effect found in
the opposite situation with wt PPT1/CLN1. This could,
however, result from a defective interaction between the
two proteins due to PPT1 mutations. To study this, we
used GST-mCLN5 to pull down overexpressed PPT1Fin
and PPT1Adult proteins from the COS-1 cell lysates. Both of
the mutated PPT1/CLN1 proteins were pulled down with
CLN5, similarly to the wt protein (Fig. 5B), demonstrating
that the interaction between the two proteins was main-
tained. These data indicated that although PPT1/CLN1
can facilitate the lysosomal trafficking of CLN5FinMajor,
CLN5 cannot rescue the restricted trafficking of the
mutated PPT1/CLN1 to the lysosomes.
Consequence of the CLN5FinMajor disease mutation on the trafficking of PPT1/CLN1 in HeLa cells Figure 4
Consequence of the CLN5FinMajor disease mutation on the trafficking of PPT1/CLN1 in HeLa cells. HeLa cells 
were transiently transfected with the wt CLN5 together with wt PPT1 (A-C), or CLN5FinMajor alone (D-F), or CLN5FinMajor car-
rying the most common vLINCLFin mutation together with wt PPT1 (G-K). The cells were fixed with methanol 48 h post trans-
fection, stained and analyzed by confocal microscopy. The wt proteins co-localized with each other completely (A-C). When 
CLN5FinMajor was expressed alone, it was retained in the ER and did not co-localize with the lysosomal marker LAMP-1 (D-F). 
When CLN5FinMajor was co-expressed with wt PPT1, the proteins co-localized in the lysosomes (G-K). Scale bar 10 μm.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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Co-immunoprecipitation and compensatory mRNA 
expression support the relationship between CLN1 and 
CLN5
Both our pull-down and trafficking experiments indicated
a strong interaction between CLN1 and CLN5, but since
this interaction was not detected in the previous co-
immunoprecipitation assay [23], we wanted to strengthen
our data with additional experiments. Therefore, we also
performed a co-immunoprecipation assay and analyzed
the mRNA expression of the binding partner protein both
in Cln1 and Cln5 deficient mice. In the co-immunoprecip-
itation assay, PPT1/CLN1 was expressed together with
mCLN5-myc/his or with a control protein ORP1L-his [32]
in COS-1 cells. mCLN5-myc/his and ORP1L-his were
immunoprecipitated with a his-specific antibody fol-
lowed by PPT1/CLN1 detection by Western blot analysis.
PPT1/CLN1 co-immunoprecipitated with CLN5, espe-
cially the tri- and diglycosylated forms, supporting the
binding of the premature ER forms of PPT1/CLN1 [26] to
CLN5. The control protein ORP1L showed no binding to
PPT1/CLN1 (Fig. 6A).
Real time PCR was performed from the cortices of wt, Cln1
and Cln5 deficient mice to detect the possible dependence
of the disruption of one binding partner on the expression
of the other. Analyses of mRNA expression levels in brain
tissues showed significant upregulation of the Cln1 mRNA
in the four-month old Cln5 deficient mice, indicating a
possible compensatory response. The mRNA levels of
Cln5 were only slightly upregulated in the brain tissue of
the Cln1 deficient mice (Fig. 6B). Altogether, these results
strengthened our novel findings and suggested a possible
functional connection between CLN1 and CLN5 proteins.
Interaction of CLN5 with the subunits of F1-ATP synthase
We have recently shown that PPT1/CLN1 co-purifies in a
large protein complex and interacts with the F1-complex
of ATP synthase [26,31]. Due to our novel findings, we
tested whether CLN5 would also interact with the F1-com-
plex. We used GST-mCLN5 to pull-down proteins from an
enriched lysosomal/mitochondrial fraction prepared
from mouse liver. Interestingly, both α- and β-subunits of
the F1-complex showed interaction with CLN5 (Fig. 7). To
test whether PPT1 or CLN5 require each other for their
respective interactions with the F1-complex, the experi-
ment was repeatedly performed using lysosomal/mito-
chondrial fractions extracted from both Cln1-/- and Cln5-/-
mice lacking the respective proteins. The β-subunit was
Consequences of the INCL disease mutations on the trafficking of CLN5 Figure 5
Consequences of the INCL disease mutations on the trafficking of CLN5. (A) HeLa cells were transiently trans-
fected with wt CLN5 and PPT1Fin, carrying the most common INCL causing mutation. Cells were fixed with methanol 48 h 
post transfection, stained and analyzed by confocal microscopy. When wt CLN5 was co-expressed with wt PPT1Fin, wt CLN5 
was able to traffic to lysosomes, whereas PPT1Fin retained in the ER. Scale bar 10 μm. (B) The GST-mCLN5 was used to pull 
down PPT1 carrying INCL disease mutations (PPTFin or the adult-onset causing mutation) and wild type CLN1/PPT1 from 
COS-1 cell lysates. Both PPTFin and the adult-onset mutations maintained their interaction with CLN5.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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able to bind both GST-hPPT1 in the absence of CLN5 and
GST-mCLN5 in the absence of PPT1, indicating that the
proteins interact with the β-subunit independent of each
other (Fig. 7). These results show that in addition to an
interaction between PPT1/CLN1 and CLN5, the proteins
share another binding partner not belonging to the group
of NCL proteins.
Discussion
Clinical and neuropathological similarities in NCL disor-
ders may result from functional redundancy or co-opera-
tion of different NCL proteins. Initial evidence of co-
operation has previously been obtained from activity
measurements and gene expression analyses. For exam-
ple, CLN2/TPP1 activity has been shown to be elevated in
other forms of NCL [23,36,37]. Furthermore, the mRNA
expression levels of a variety of NCL genes have been
reported to be altered in different NCLs [22]. Recent stud-
ies of animal models have further supported a common
mechanism in the disease pathogenesis of the NCLs.
Selective loss of interneurons, early defects on thalamo-
cortical neuron survival as well as early glial responses are
detected in different mouse models as well as in large ani-
mal models [8,38]. Molecular interactions between NCL
proteins have also been reported previously [23,39]. Here
we continued the search for NCL protein interactions and
their intracellular consequences. We demonstrate that
CLN5 has molecular connections to at least to five other
NCL proteins, namely CLN1/PPT1, CLN2/TPP1, CLN3,
CLN6 and CLN8, suggesting a central role for CLN5 in the
NCL network.
Mutations of CLN5 and consequent trafficking defects can
result in functional consequences on the interacting pro-
Association between CLN5 and PPT1/CLN1 Figure 6
Association between CLN5 and PPT1/CLN1. (A) 
COS-1 cells were transiently transfected with PPT1/
CLN1 together with mCLN5-myc/his or ORP1L-his. Co-
immunoprecipitation was performed with a his-specific 
antibody, followed by Western blot detection for PPT1/
CLN1. CLN5 was found to bind specifically with PPT1/
CLN1, confirming the interaction between the proteins. 
(B) RNA was extracted from the whole cortical area of 
four Cln5-/- mice, four Cln1-/- mice and four of their respec-
tive wt littermates and pooled together into two wild-
type and two knock-out samples. Real time RT-PCR was 
then performed to measure expression of the two NCL 
proteins. The value for the wt gene expression was set to 
1 and Cln5 and Ppt1 expression values are shown relative 
to that. Expression of CLN1 (black columns) was over 
two-fold up-regulated in the 4-month-old Cln5-/- mice 
compared to that of the wt. The expression of CLN5 
(gray columns) was only slightly altered in Cln1-/- mice of 
the same age.
Interaction of CLN5 with the α- and β-subunits of the ATP  synthase Figure 7
Interaction of CLN5 with the α- and β-subunits of the 
ATP synthase. GST-hPPT1 and GST-mCLN5 fusion pro-
teins were used to pull down interacting proteins from 
enriched lysosomal/mitochondrial fraction extracted from 
the liver of wild type Cln1-/- and Cln5 -/- mice. The bound pro-
teins were analyzed by Western blot using monoclonal anti-
bodies for α- and β-ATP synthase. Load = 10 μg of total 
protein from mouse liver extract.BMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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teins, as well as in changes in their distribution. Most NCL
proteins are not, however, detectable endogenously by
immunofluorescence analyses using the currently availa-
ble antibodies and therefore this hypothesis could not be
tested in patient fibroblasts. However, simultaneous over-
expression of binding partners with the modified, trans-
port incompetent CLN5-TD (CLN5-flag330) construct
suggested that the interaction between PPT1/CLN1 and
CLN5 is strong and occurs already in the ER, where the
interactions between CLN5 and the two ER resident NCL
proteins, CLN6 and CLN8, would also naturally occur.
Since CLN5 resides in the lumen of intracellular
organelles, interaction between CLN5 and the transmem-
brane proteins must be mediated by the lumenal domains
of these proteins. The finding that NCL interactions can
occur already in the ER is important since previous studies
have also suggested that the ER is an important organelle
for the function and/or trafficking of NCL proteins. For
example, CLN3 carrying the most common JNCL muta-
tion [40] has been reported to preserve a significant func-
tion in the ER. Although the mutated CLN3 is retained in
the ER, it was shown to be able to affect the size of lyso-
somes [41]. Furthermore, our data suggest that TPP1/
CLN2, another lysosomal enzyme, is likely to interact
with CLN5 only in the late endosomes/lysosomes. This
was supported both by the interaction analysis and the
unaffected transport of CLN2. Therefore, the present data
suggest that interactions between CLN5 and other NCL
proteins can occur along the secretory pathway, and the
interactions are not strictly dependent on the steady-state
localization or the solubility of the NCL proteins.
Based on our trafficking experiments, the main focus was
on the interaction between PPT1/CLN1 and CLN5. Unlike
the transport deficient, strictly ER-resident CLN5-TD, the
ER exit competent CLN5FinMajor did not prevent the lyso-
somal trafficking of PPT1 but rather, PPT1 was able to
facilitate the trafficking of the mutated CLN5 from the ER
and Golgi to the lysosomes. Lysosomal proteins have also
previously been shown to assist each other in their lyso-
somal trafficking. For example, the CLC7 chloride trans-
porter, involved in an NCL-like disorder in mouse, has
been shown to facilitate the transport of Ostm1 to the lys-
osomes, where the proteins act together in lysosomal
chloride transport [42]. It was also recently demonstrated
that the lysosomal membrane protein LIMP-2 is required
for the mannose 6-phosphate receptor-independent tar-
geting of β-glucocerebrosidase. Interestingly, the overex-
pression of LIMP-2 was also able to facilitate the transport
of the mutated, trafficking deficient β-glucocerebrosidase
from the ER to the lysosomes [43]. Both PPT1 and CLN5
are soluble intravesicular proteins and are not able to
interact with cytoplasmic sorting and transport machinery
per se, like CLC7 and LIMP-2. However, trafficking of
CLN1/PPT1 has been reported to show properties differ-
ent from classic lysosomal enzymes [26] and we have
recently discovered that also CLN5 can use M6PR-inde-
pendent pathways for its lysosomal trafficking (our
unpublished observations). Therefore, it is possible that
the formation of the CLN1-CLN5 complex may be impor-
tant for utilizing other trafficking pathways than the clas-
sical M6PR pathway. In which circumstances this is
required in vivo, remains to be studied in further experi-
ments.
A close connection between PPT1/CLN1 and CLN5 has
already been suggested in previous studies. The proteins
share similar expression patterns in the mouse brain and
in the prenatal human brain [16,21,44,45]. Our recent
global gene expression profiling analyses of the Cln1-/- and
Cln5-/- mouse brains implicated a common defective path-
way mediated by phosphorylation and potentially affect-
ing the maturation of axons and neuronal growth cones
[46]. Here, we provide further evidence for a tight rela-
tionship between the two proteins by showing not only
the interaction between the proteins but also, demonstrat-
ing significantly increased expression levels of Cln1
mRNA in the Cln5-/- mouse brain tissue. This suggests a
possible compensatory role for PPT1 in CLN5 deficiency.
Functional connection of CLN5 and PPT1 is also sug-
gested by the shared interaction partner not belonging to
the NCL protein family, the F1-ATP synthase. The ectopic
F1-ATP synthase has been shown to function as an apoA-I
receptor on the plasma membrane [47] and both the
amount of the F1-complex as well as the uptake of apoA-I
have been shown to be increased in Cln1-/- mouse neurons
[31]. Therefore, both PPT1 and CLN5 could be connected
to the maintenance of lipid homeostasis. In general, accu-
mulating evidence has indicated dysregulated lipid
metabolism in different forms of NCLs and several NCL
proteins have been functionally linked to lipid metabo-
lism [[48,49], reviewed in [50-52]].
Conclusion
In this study, we show novel interactions between the
neuronal ceroid lipofuscinosis protein CLN5 and five
other NCL proteins. Consequently, our study strengthens
the long-term hypothesis of a common cellular pathway
behind the NCLs and suggests that different mutations in
a given NCL protein may lead to different pathological
outcomes through variable distinct effects on the NCL
protein network. The strongest interaction was detected
between CLN5 and PPT1/CLN1, and PPT1/CLN1 was
shown to be able to contribute to the intracellular traffick-
ing of the mutated CLN5, the phenomenon, which may
be important when planning the therapy for vLINCLFin.
Deficiency of Cln5 was also shown to result in upregula-
tion of Cln1 expression in the mouse brain, suggesting a
dependency for CLN1/PPT1 over CLN5. For the first time,
the two NCL proteins were shown to share an interactionBMC Cell Biology 2009, 10:83 http://www.biomedcentral.com/1471-2121/10/83
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partner outside the NCL protein spectrum, since CLN5
and PPT1 both interacted with the F1-complex of the ATP
synthase. This finding may be important in characteriza-
tion of the cellular functions of the NCL proteins.
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